arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

NextCure, Inc.

NXTC
$5.88 ▲ +0.36 (+6.52%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
9 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

NextCure, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $16.7M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -130.3%
FCF / Share $-17.45
Trailing P/E
Price / Book 0.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$22.38M
↑ +252.6%
Net Income Profit after all expenses
$-55.84M
— -0.3%
FCF / Share Free cash flow per share
$-17.45
↑ +5.4%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
4
Financial Health
5
Cash Quality
60

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters